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Abstract
Research examining variables that influence medication adherence among HIV-positive
individuals remains an important priority. The patient-provider relationship may influence HIV
medication adherence, though findings have varied across studies and there is a paucity of
research examining mechanisms that may account for patient-provider influences on adherence.
One potential mechanism that may explain this relationship is patient’s beliefs about
medications, specifically how patients weigh the necessity of medications relative to concerns
about negative side effects. Using data from a sample of 116 HIV patients recruited during
outpatient care, this study aimed to (a) examine the effect of the patient-provider relationship on
both adherence and intentional nonadherence; and (b) clarify whether there is an indirect effect
of this relationship through medication beliefs. Primary study hypotheses were tested using
bootstrapped mediation models. Results showed that the patient-provider relationship was
positively associated with adherence but not intentional nonadherence. There was strong support
for an indirect effect of this relationship through medication beliefs for adherence but not
intentional nonadherence. This study could inform interventions to improve the patient-provider
relationship as well as target potentially modifiable patient beliefs about their medications.
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The Patient-Provider Relationship and HIV Medication Adherence: Indirect Effects of
Medication Beliefs
There are an estimated 1.2 million people living with HIV/AIDS (PLWHA) in the United
States and more than 36 million worldwide (World Health Organization; WHO, 2016). With
approximately 40,000 new infections per year in the United States and over 2 million worldwide
(WHO, 2015), stemming the HIV epidemic remains an important public health priority. Over the
past decade, the lifespan of those newly infected with HIV has nearly doubled (Samji et al.,
2013) and HIV is now widely considered a manageable chronic condition by physicians and
public health experts (Deeks, Lewin, & Havlir, 2013). However, strict adherence to highly active
antiretroviral therapy (HAART) is of critical importance to avoid disease progression and
prevent viral resistance (Paterson et al., 2000). Despite significant treatment advances, poor
medication adherence (defined as below 90-95% of prescribed doses) remains common
(Cambiano, et al., 2010). Indeed, a recent meta-analysis by Ortego & colleagues (2011) found
that only 62% of those prescribed HAART adhere to recommended guidelines.
Identifying patient factors that contribute to medication adherence difficulties is of vital
importance, as poor adherence is associated with lower CD4 counts and a higher viral load
(Paterson et al., 2000). These factors contribute to the HIV epidemic by increasing HIV
transmission risk (Attia, et al., 2009) and highlight the importance of treatment as prevention
guidelines as well as test and treat strategies (WHO, 2016). Substandard adherence may lead to
the development of drug-resistant HIV strains (Hatano & Deeks, 2007; Rosenbloom, Hill, Rabi,
Siliciano, & Nowak, 2012), increased risk for opportunistic infections (Swindells et al., 2002),
and increased risk for virologic failure (Aberg et al., 2013; Paterson et al., 2000). Further, poor
adherence to one class of drugs that are commonly used in HAART regimens, Non-Nucleoside
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Reverse Transcriptase Inhibitors (NNRTI’s) can lead to cross-resistance of the entire NNRTI
class of drugs (Li et al., 2005; Parienti, et al., 2004). Given the role of adherence in predicting
treatment success, researchers have emphasized the importance of identifying potentially
modifiable factors that influence adherence (Beach et al., 2006).
Research has identified a number of patient-specific factors associated with adherence
among PLWHA. For example, social support and adherence self-efficacy are positively
associated with adherence, while depressive symptoms, current substance use, and HIV-related
stigma have been found to be negatively associated with adherence (Langebeek et al., 2014).
Although patient and treatment related variables have been studied extensively among PLWHA,
one risk factor that has received attention in recent years concerns the relationship between
patients and their treatment teams, and more specifically the patient-provider relationship (Beach
et al., 2006). The quality of the patient-provider relationship has been shown to improve
adherence among chronic disease patients (Stange et al., 2010), and recent data suggests that
specific components of the patient-provider relationship may play a role in HAART adherence
(Langebeek et al., 2014). Interest in the role of patient-provider relationships and adherence
among PLWHA is in keeping with growing recognition of the importance of patient-provider
relationships across all of health care (Swick et al., 1999).
Among PLWHA, the advent of HAART and the prospect of long term survival enhanced
the importance of collaborative patient-provider interactions, where patients make decisions
alongside their providers (Wagner et al., 2005). Accordingly, research has focused on
understanding the impact of several aspects of the patient-provider relationship on adherence,
including provider trust, communication, disease-specific information, collaboration, and
satisfaction (Ironson, Lucette, & McIntosh, 2015; Schneider, Kaplan, Greenfield, Li, & Wilson,
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2004). While a number of studies have documented the importance of the patient-provider
relationship as a determinant to medication adherence among PLWHA (Beach et al., 2006;
Oetzel et al., 2015; Langebeek et al., 2014), other studies have failed to find an association
between the patient-provider relationship and adherence (Moralejo, et al., 2006; Holmes et al.,
2007; Kalichman, Ramachandran, & Catz, 1999), and one study found that better provider
communication and interpersonal skills predicted poorer adherence (Ingersoll & Heckman,
2005). Further, only a few studies have sought to identify factors that may clarify mechanisms
linking aspects of the patient-provider relationship to adherence.
Whereas a lack of trust, or a poor relationship with one’s provider may undermine
engagement in healthcare generally, the impact of the patient-provider relationship on adherence
may be explained in part by the influence of the patient-provider relationship on beliefs about
medications. Medication beliefs have been shown to negatively impact treatment adherence
(Nozaki et al., 2013). Horne and colleagues (1999) developed an approach to explain nonadherence that emphasizes patient’s beliefs about the necessity of medications and concerns
related to negative effects of medications. Specifically, the extent to which patients rate their
need for medication relative to their concerns about medication, operationalized as a differential
score, is a strong predictor of medication adherence across chronic health conditions, including
HIV (Horne et al., 2013). Preliminary findings suggest that the association between the patientprovider relationship and adherence may be partially explained by medication beliefs (Altrice et
al., 2001; Gauchet et al., 2007).
The present study aimed to clarify the effect of provider trust and satisfaction on
medication adherence and examine the role of patient beliefs as a potential mechanism linking
the patient-provider relationship to adherence. Hypotheses were generated based on the past
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findings concerning the effect of the patient-provider relationship on HAART adherence and
research pointing to the role of medications beliefs as a mechanism for explaining the effect of
the patient-provider relationship on adherence.
Patient-Provider Relationship among PLWHA
The patient-provider relationship in HIV care first received attention during the late
1990’s in a series of qualitative studies that documented how provider knowledge, interpersonal
skills, and personalized-care were often described as contributing to better adherence (Bakken et
al., 2000; Roberts 2000). Trust in one’s providers is considered a cornerstone of modern
medicine, as care is presumed to be optimized when patients trust their provider to have their
best interest in mind (Hall, Dugan, Zheng, & Mishra, 2001). Trust is especially important as
many PLWHA report experiencing stigma (Lowther, Selman, Harding, & Higginson, 2014),
including a significant minority who report stigmatizing experiences in healthcare settings
(Naughton & Vanable, 2013; Nyblade, et al., 2009). Further, medical mistrust, which includes
mistrust of one’s provider, is especially high among men who have sex with men (MSM) and
African-American communities, two groups that are especially vulnerable to HIV infection
(Halbert, Armstrong, Gandy, & Shaker, 2006; Santos et al., 2013).
Among PLWHA, provider trust, which includes honesty, fidelity, and confidentiality, has
generally been associated with better adherence across numerous qualitative and quantitative
studies (Hall et al., 2001). Indeed, one recent meta-analysis (Langebeek et al., 2014) found that
both provider trust and satisfaction was associated with better adherence. However, the included
studies varied considerably in their measurement of the patient-provider relationship and pooled
trust and satisfaction together. Other researchers consider these distinct variables, as trust
involves a level of risk in the decision to be vulnerable with another person (Blackstone et al.,
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2012; Thom & Campbell, 1999). Among cross-sectional studies, low provider trust has been
linked to poorer medication adherence among PLWHA in prison settings (Altice, Mostashari, &
Friedland, 2001), urban HIV clinics (Blackstock et al., 2012), Southern Infectious Disease (ID)
clinics (Whetten et al., 2006), and among African HIV clinics (Watt et al., 2010). In contrast,
Holmes and colleagues (2007) found that among 116 HIV positive patients, provider trust was
not associated with adherence over a 12-month period. Despite some mixed findings, these
results suggest that provider trust may play a key role in adherence outcomes. However, there is
a significant lack of empirical data on the mechanisms that may help to explain the ways in
which provider trust enhance or diminish medication adherence.
Another widely studied factor is provider satisfaction, which refers to a patient’s
appraisal of the services received based on interactions with their provider (Crow, Gage,
Hampson, & Hart, 2003). A number of studies have investigated the influence of provider
satisfaction on adherence, with mixed results. For example, provider satisfaction has been
associated with better adherence in a sample of outpatients from both the United States
(Schneider et al., 2004) and Canada (Godin et al., 2005). In contrast to these findings, several
studies have failed to find a direct relationship between satisfaction and adherence. For example,
provider satisfaction was not associated with adherence in outpatients from Sweden
(Schonnesson et al., 2006), Spain (Moralejo et al., 2006), and rural areas throughout the United
States (Cosio, et al., 2010). Among studies examining provider satisfaction and adherence, only
one examined potential mediators of this association. DiIorio and colleagues (2009) found a
positive relationship between patient satisfaction and adherence, and their final model showed
that provider satisfaction indirectly influenced adherence through self-efficacy and depression.
Taken together, findings provide only mixed support for the impact of provider satisfaction on
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adherence and only limited data on potential mediating variables that may explain this
relationship.
Research is needed to clarify the extent to which patient-provider variables influence
patient behavior, as is research that clarifies potential mechanisms to explain these relationships.
One possible mechanism linking provider relationship variables to adherence is the impact that
the patient-provider relationship may have on patient’s medication beliefs. An understanding of
the interconnection between the patient-provider relationship and patient’s medication beliefs has
the potential to improve adherence focused interventions (Beach et al., 2015).
Testing the Indirect Effect of Medication Beliefs in the
Patient-Provider to Adherence Relationship
Given the importance of patient-provider relationships in HIV care, research is needed to
clarify the role of specific patient-provider relationship variables on adherence and to clarify
psychological factors that may explain the ways in which provider level variables shape health
behavior outcomes. It is conceivable that patient-provider relationships affect adherence by
simple virtue of the fact that doctors instruct patients to take medicine as prescribed. Effective
patient education leads to medication taking behaviors, and the extent to which patients follow
through with instructions would depend primarily on the clarity of the patient education.
Researchers have proposed a second possibility, namely that the strength of the patient-provider
relationship influences adherence levels in so far as relationship factors help to solidify patient’s
beliefs about the need for medication. For example, if a patient trusts their providers, they may
be more likely to internalize statements made about the importance of taking medication as
prescribed as a means of maintaining health. On the other hand, if a patient does not trust their
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providers, they may believe their providers are attempting to minimize the actual side effects of a
medication. In turn, these beliefs about medications may influence a patient’s adherence.
The present study tested the hypothesis that patient’s beliefs about the necessity of
medication and concerns about side effects will mediate the effect of the patient-provider
relationship on adherence. This perspective is in keeping with that which is proposed by the
Necessity/Concerns Framework (Horne et al., 2004). Drawing from self-regulation theory,
Reynolds (2003) proposed a self-regulatory model to explain the numerous factors involved in
adherence behavior in patients with chronic illness. Self-regulation theory (Diefenbach &
Leventhal, 1996; Leventhal et al., 1997) suggests that people develop a representation of their
illness based on background experiences such as their relationship with their providers, as well
as the method of treatment (e.g., medication). While complex in nature, research has
demonstrated that beliefs about medications fall under two categories: perceptions related to the
necessity of a medication and concerns about adverse side effects (Horne et al., 2004; Horne,
Weinman, & Hankins, 1999). A key consideration in this theory is the importance of the
differential between the necessity and concerns beliefs. For example, a patient who believes their
medications are not important to their long-term health and report several concerns related to
side effects may be less likely to take their medications as prescribed. One recent meta-analysis
(Horne et al., 2013) identified these two factors as a strong predictor of adherence among
PLWHA. Given that providers play a critical role in educating patients by addressing concerns
and emphasizing the necessity of medications (Altice, Mostashari, & Friedland, 2001), it is
possible that beliefs about medications can explain the effect of the patient-provider relationship
on medication adherence.
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To date, only one study has investigated the role of both necessity and concerns related to
medications as a mediator of the association between patient-provider relationships and
medication adherence. Gauchet, Tarquinio, and Fischer (2007) used a structural equation
modeling approach to evaluate the relationship between HIV patients’ confidence in their
provider, beliefs about medication and adherence. Their results showed higher provider
confidence predicted greater adherence, and this relationship was partially mediated by patients’
beliefs in the necessity of HIV medications, but not concerns about medication side-effects.
Conceptually, this suggests that patients’ beliefs about the necessity of their medications are
influenced by interactions with their provider. The authors tested an additional model where
beliefs about medications and provider confidence were reversed. That is, beliefs about
medications predicting medication adherence, mediated by provider confidence. Importantly, the
fit was less optimal, suggesting that confidence in the provider is influencing patients’ beliefs
about their medication, and not the other way around. Results from this study are consistent with
the notion that patients’ medication beliefs are formed, in part, by the confidence ascribed to
interactions with their health care provider.
The study by Gauchet and colleagues (2007) has several limitations. First, the study
evaluated only one aspect of the patient-provider relationship (confidence). There is evidence
from meta-analytic work that other aspects of the patient-provider relationship, such as trust and
satisfaction are relevant to medication adherence (Langebeek et al., 2014). Second, the authors
used the original 18-item Beliefs about Medicines Questionnaire (BMQ) and related four
subscales (Specific-Necessity, Specific-Concerns, General Overuse, General Harm) rather than
the HIV-specific BMQ-HAART. In their final model, they included three additional variables
related to values which may have confounded their results. Further, previous research has found
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that the interaction between necessity beliefs and concerns is a stronger predictor of adherence
than either variable alone (Horne et al., 2004). Specifically, Horne and colleagues (2004) found
that patients were more likely to report lower adherence if their concerns about medications were
high relative to their perception of the necessity of HAART. Finally, the authors used a measure
of adherence that created a total medication adherence score. This methodology fails to capture
more deliberate decisions to skip or alter doses, which can be classified as intentional
nonadherence (Wroe, 2002). Several studies in HIV-infected patients have found rates of
intentional nonadherence from 11%-20% (Heath et al., 2002; Mo & Mak, 2009). Further, Norton
and colleagues (2010) found that patients who reported intentionally skipping doses were more
likely to report difficulty talking to their health care provider. Thus, intentional nonadherence
may reflect a poor patient-provider relationship and including such a measure will allow better
understanding of the mechanisms involved.
Current Study
The current study aimed to clarify the association between the patient-provider
relationship as measured from the patient’s perception, and HAART adherence using the
Necessity/Concerns Framework. First, this study examines the effect of provider trust and
satisfaction on adherence and intentional nonadherence. It was hypothesized that both provider
trust and satisfaction will be positively associated with overall medication adherence levels and
negatively associated with engagement in intentional nonadherence. Next, this study examines
the ability of the Necessity/Concerns Framework to explain the association of provider trust and
satisfaction on adherence. It was hypothesized that there will be an indirect effect of the patientprovider to adherence relationship through medication beliefs, as measured by the necessityconcerns differential, (i.e., difference between perceived necessity of medications relative to
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concerns about medications, see Figure 1). Specifically, patients who report more positive
relationships with their providers will endorse more necessity beliefs relative to concerns beliefs
which will in turn lead to increased medication adherence and decreased engagement in
intentional nonadherence. Those patients who report poor relationships with their providers will
endorse more concerns beliefs relative to necessity beliefs which will lead to decreased
medication adherence and increased engagement in intentional nonadherence.
This study is the first to investigate the effect of the patient-provider relationship on both
adherence and intentional nonadherence in a sample of PLWHA while examining the role of
medication beliefs as defined by the Necessity/Concerns Framework. The results from this study
will help to elucidate malleable factors that can be targeted by interventions aimed at providers
or patients. Study hypotheses were tested using data from 116 patients participating in a study
examining barriers to health and coping in the context of HIV care (see Littlewood and Vanable,
2013).
Methods
Participants
A total of 150 participants from Upstate New York (41% female, 57% male, 2%
transgender) were recruited for study participation during an outpatient HIV care visit. For the
present study, participants were required to be current HAART users, bringing the final sample
size to 116. The average age was 44 years old (range 19-64). 48% of participants self-identified
as African-American, 41% as Caucasian, 6% as Multi-Racial, 4% as Native American, and 1%
as Pacific Islander. The average time elapsed since HIV diagnosis was 11 years and 59% of our
sample reported their viral load was currently “undetectable” (viral load <50). The majority of
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participants were unemployed (62%), 19% of participants did not have a high school diploma,
37% had a high school degree, and 43% reported at least some college.
Procedures
Participant recruitment. Participants were recruited during routine outpatient HIV care
visits. Patients were informed about the opportunity to participate in the study by a clinic staff
member. Verbal consent to be approached by the research team was obtained by a health care
provider before a patient was asked about study participation. A second source of study
participants was through a pool of past study participants who had previously agreed to be
contacted regarding future studies opportunities. Informed consent was obtained from all
participants before data collection. Eligible participants were HIV-positive, at least 18 years old,
currently undergoing HAART treatment, English-speaking, and capable of providing informed
consent. Participants were compensated $20 upon study completion.
Survey administration and data entry. The questionnaires were administered using audio
computer-assisted self-interviewing (ACASI). ACASI has been shown to increase patient’s
disclosure of sensitive information over traditional interviews (Schroder, Carey, & Vanable,
2003). Surveys were completed in a private room and required roughly one hour to complete.
Survey data was exported to SPSS and merged with medical chart data. All statistical analyses
were conducted using SPSS v16.0 (Statistical Package for the Social Sciences; SPSS Inc.,
Chicago, IL).
Measures
Demographics. Data obtained from self-report included age, education, income, ethnicity,
employment status, duration of HIV medication usage, and sexual orientation.
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HAART adherence. Items assessing HAART adherence were adapted based on research
conducted by Simoni and colleagues (2006). Self-reported adherence was assessed for the past
week and past month. For the past week, participants completed a timeline follow back (TLFB)
for the past seven days. The TLFB asks participants to report the number of pills they are
supposed to take every day and how many they actually took. From these data, a past-week
adherence score is calculated (prescribed doses – missed doses) / (prescribed doses) x 100. The
advantage of assessing adherence for the past week compared to past several days is that a
weekend will always be included, and previous research has shown adherence is often
problematic on weekends (Bachhuber et al., 2010). Additionally, these data may allow us to
differentiate those who are consistently adherent from those who are typically less adherent, but
have better adherence over shorter periods (Simoni et al., 2006). For the past month, HAART
users completed a visual analog scale (VAS) ranging from 0-100% where they estimated the
amount of HIV medications they took. Past month adherence was dichotomized as ≥ 95% or <
95%, consistent with previous research (Viswanathan et al., 2015).
Intentional nonadherence since HIV diagnosis. To capture the prevalence of intentional
nonadherence occurring since the time of diagnosis, 16 items assessed four domains consistent
with previous research (Laws et al., 2000; Littlewood & Vanable, 2013; Roberts & Mann, 2003):
(1) Treatment uptake, whereby patients declined to begin taking HAART despite
recommendations from their physician; (2) treatment interruption, in which patients stopped
taking some or all of their medications without telling their provider; (3) medication vacation,
where patients “took a break” of more than one day from some or all of their medications; and
(4) medication changes, representing any intentional alterations to their HAART regimens (e.g.,
taking less than prescribed, taking a dose later than scheduled, doubling up on their dosage to
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make up for a missed dose, or skipping any special instructions). A score of 1 was assigned for
each category with a positive response, and the sum of these scores yielded an intentional
nonadherence composite score (range 0-4). This measure assesses the underlying motivation of
intentionally nonadherent patients as patients make decisions about treatment based on a wide
range of factors (Wroe, 2002).
Intentional nonadherence, past month. To estimate the extent of intentional nonadherence
in the past month, participants were asked how often they made changes to their prescribed
HAART regimens or skipped a dose of their medication for personal reasons (e.g., feeling
depressed, side effects, change in plans, or other). Participants indicated their response by
placing a mark on a visual analog scale with anchors (0 = Never, 50 = About half the time, 100 =
All the time). A single intentional nonadherence score for the past month was calculated by
taking the average of these items. This measure was included in addition to the previous lifetime
assessment of intentional nonadherence to ensure answers were based on their current provider
(e.g., patients may have engaged in different behaviors with a prior provider).
Beliefs About Medications. To assess patients beliefs about HAART medications, the
validated Beliefs about Medicines Questionnaire – HAART version (BMQ-HAART) was used
(Horne et al., 1999). Two subscales were used for the present study: perceived necessity of
HAART and concerns about potential adverse consequences of using HAART. Items related to
the perceived necessity of HAART refer to participant’s beliefs that taking HAART is necessary
for their health and longevity. The necessity subscale consists of 8 items such as “My health
depends on HIV medications” and “HIV meds can keep me alive”. Items related to concerns
about adverse consequences refer to both concerns about long term effects of HAART use and
more tangible concerns such as side effects or embarrassment from medication use. The
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concerns subscale consists of 11 items such as “My HIV meds give me unpleasant side-effects”
and “Having to take HIV meds worries me”. Patients were asked to rate their agreement of 19
statements about HIV medications using a 5-point Likert scale with a range of “strongly agree”
to “strongly disagree.” Internal reliability for both scales was good (alpha = .70 for necessity and
.74 for concerns) and is consistent with other samples (Horne et al., 2004).
Consistent with previous methodology (Horne et al., 2004; Horne et al., 2007), a
necessity-concerns differential was calculated by computing mean scores for both subscales and
subtracting concerns scores from necessity scores (range -4: 4). This differential score reflects
how patients rate the necessity of medication relative to their concerns and has been shown to be
a stronger predictor of adherence than either subscale alone (Horne et al., 2007). As such, the
model for the present study will test this differential score as a potential mediator of the patientprovider to adherence relationship. Higher differential scores reflect patients placing more value
on the necessity of medication relative to concerns about medication.
Patient-Provider Relationship. The quality of the patient-provider relationship was
assessed using 26 items based on previous work by Schneider and colleagues (2004). For the
present study, the subscales of provider trust (3-items) and provider satisfaction (3-items) were
of interest. Items related to overall satisfaction with their treatment team (e.g., Overall, how
would you rate your provider’s personal manner?) were rated on a 5-point Likert scale from 1
(Poor) to 5 (Excellent). Items related to trust in their treatment team (e.g., I can tell my HIV care
provider anything, even things that I might not tell anyone else) were rated on a 6-point Likert
scale from 1 (Strongly Disagree) to 6 (Strongly Agree) while one item (All things considered,
how much do you trust your HIV care provider?) was rated on a 5-point scale of 1 (Not at all) to
5 (Completely). Of note, this measure captures the patient’s perception of their relationship with
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providers. Internal reliability for both subscales in this sample was good (alpha for satisfaction =
0.96 and for trust, alpha = 0.83) and is consistent with other studies (Schneider et al., 2004).
Data Analytic Plan
Power analyses were conducted to determine if the primary hypotheses could be tested
using this sample of 116 patients with at least the 0.8 minimum statistical power
recommendation for mediation analyses (Fritz & Mackinnon, 2007). The only study to test the
patient-provider to adherence relationship mediated by medication beliefs found a small-medium
effect of the provider relationship on medication beliefs and a small-medium effect of
medication beliefs on adherence (Gauchet et al., 2007). Of note, the authors used a different
measure of the patient-provider relationship and medication beliefs. Nonetheless, these estimates
were used to guide the current study. The effect of the patient-provider relationship on
medication beliefs and the effect of medication beliefs on adherence was estimated to be smallmedium. An a-priori sample size calculation suggested a total sample size of 92. The sample size
of the present study exceeds this sample size; thus, this study has acceptable statistical power.
All statistical analyses were conducted using SPSS version 16 (SPSS Inc., Chicago, IL).
First, descriptive statistics were conducted to characterize the sample. Next, bivariate
correlations were examined for hypothesized associations of the patient-provider relationship,
beliefs about medications, and both medication adherence and intentional nonadherence. Finally,
mediation models (see Figure 1) tested the effect of provider trust on the mediator (beliefs about
medications, a path), the effect of the mediator (beliefs about medications) on both outcomes
(adherence and intentional nonadherence, b path), and the effects of provider trust on both
outcomes (adherence and intentional nonadherence, c path). Next, two additional mediation
models (see Figure 1) tested the effect of provider satisfaction on the mediator (beliefs about
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medications, a path), the effect of the mediator (beliefs about medications) on both outcomes
(adherence and intentional nonadherence, b path), and the effects of provider satisfaction on both
outcomes (adherence and intentional nonadherence, c path).
To ensure the causal path represents the most viable model fit, several alternative
mediation models were tested. It may be possible that beliefs about medications influence the
patient-provider relationship, rather than vice versa. In these models, the necessity-concerns
differential was entered as the independent variable, and both provider trust and satisfaction
were entered as mediators in separate models with adherence and intentional nonadherence as
outcomes.
Analyses were conducted using an SPPS macro designed to examine mediation models
using bootstrapping methods (PROCESS; Preacher & Hayes, 2008). The macros provide path
coefficients for the mediation models and bootstrapped 95% confidence intervals for the indirect
effect of provider satisfaction and provider trust on both outcomes of adherence and intentional
nonadherence via beliefs about medications.
Results
Descriptive Findings
As shown in Table 1, participants reported moderate to high levels of trust in and
satisfaction with their providers (M’s = 4.59 and 4.38 respectively). With regard to medication
beliefs (the necessity-concerns differential), participants reported a lower number of concerns (M
= 2.46; SD = .64) relative to necessity beliefs (M = 4.33; SD = .57). On average, participants
reported taking 92% of their prescribed medications in the previous week and 90% of their
prescribed medications in the past month. Approximately 90% of patients reported ≥ 95%
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adherence in the past month. The average rate of intentional nonadherence over the past month
was 18%.
Association of Trust and Satisfaction to Adherence
The first set of analyses examined the hypothesis that both provider trust and satisfaction
would be positively associated with medication adherence and negatively associated with
intentional nonadherence. Consistent with this hypothesis, provider trust was positively
associated with past week adherence (r = .34, p < .05; Table 2) and past month adherence (r =
.18, p = < .05). Provider satisfaction was also positively associated with past week adherence (r =
.21, p < .05) and past month adherence (r = .23, p < .05). Provider trust was negatively associated
with past month intentional nonadherence (r = -.24, p < .05) but was not associated with lifetime
intentional nonadherence. Provider satisfaction was not associated with either past month
intentional nonadherence or lifetime intentional nonadherence.
Tests of the indirect effect of medication beliefs on 7 Day and 30-Day Adherence
Tables 3 and 4 provide comprehensive statistical information for each model. Path results
common to multiple models are reported only in the first model in which they appear. For all
models, covariates of age, gender, and time on HAART were included, as these factors have
been linked with poorer adherence (Beer & Skarbinski, 2014).
A major goal of this study was to test the hypothesis that there would be an indirect effect
of provider trust on adherence via beliefs about medications. Regression analyses established
that provider trust was not associated with past 30-day adherence while beliefs about
medications trended toward significance (b: β = .372; z = 1.905; p = .057). Based on 10,000
bootstrap re-samples, the indirect effect of provider trust on 30-day adherence via mediation
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beliefs was positive and significant (Table 4: OR = .184; SE = .990; 95% CI: .251 to 4.14). The
model with 7-day adherence as the dependent variable was not significant.
The next model replaces provider trust with provider satisfaction, variables that are
moderately correlated with one another (r = .65, p < .001). Provider satisfaction was not
associated with 7-day adherence in the model but was associated with medication beliefs (a: β =
0.289; t = 2.855; p < .01). Medication beliefs and 7-day adherence were positively associated (b:
β = 3.331; t = 2.312; p = 0.023). Based on 10,000 bootstrap re-samples, there was a significant
positive indirect effect of provider satisfaction on 7-day adherence via medication beliefs (Table
4: β = .961; SE = .634; 95% CI: .126 to 2.71). Given that adherence may vary on a week-to-week
basis, the model was tested again with 30-day adherence as the outcome. Regression analyses
established that provider satisfaction was not associated with 30-day adherence while medication
beliefs was positively associated with 30-day adherence (b: OR= .442; z = 2.351; p = .019).
Based on 10,000 bootstrap re-samples, there was a significant positive indirect effect of provider
satisfaction on 30-day adherence via medication beliefs (Table 4: β = .127; SE = .084; 95% CI =
.021 to .344).
Indirect Effect of Medication Beliefs in Relation to Intentional Non-Adherence
A second primary goal of the present study was to test whether there is an indirect of the
patient-provider to adherence relationship through medication beliefs. It was hypothesized that
the patient-provider to intentional nonadherence relationship would be partially influenced by
medication beliefs such that better patient-provider relationships would lead to a higher
necessity-concerns differential, and lower engagement in intentional nonadherence. To examine
this hypothesis, the previous models were run replacing the outcome of medication adherence
with intentional nonadherence. Based on 10,000 bootstrap re-samples, the indirect effects of
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provider trust on both measures of intentional nonadherence through medication beliefs were not
significant. Model 4 (Table 3) tests the indirect effect of provider satisfaction to intentional
nonadherence through medication beliefs. There was a significant negative indirect effect of
provider satisfaction on lifetime intentional nonadherence via beliefs about medications (Table 4:
β = -.056; SE = .036; 95% CI: -.153 to -.004). Regression analyses established that provider
satisfaction was not associated with lifetime intentional nonadherence while medication beliefs
(b: β = -.195; t = -1.977; p = .05) was associated with lifetime intentional non-adherence. Neither
model with past 30-day intentional nonadherence as the outcome was significant.
Alternative Models
Given the possibility that beliefs about medications influence the patient-provider
relationship, rather than vice versa, several alternative models were examined (Table 4).
Medication beliefs were entered as the independent variable and both provider trust and
satisfaction were entered as mediators in separate models. In these models both past week and
past month adherence, as well as past month and lifetime intentional nonadherence were entered
as the dependent variables. All models with provider satisfaction as the mediator were not
significant. However, the indirect effect of medication beliefs to past week adherence via
provider trust achieved significance (β = 1.731; SE = 1.101; 95% CI: .232 to 4.86).
Given the use of a difference score as a mediator, additional models were run with both
necessity beliefs and concern beliefs entered in parallel. Results confirmed a significant indirect
effect of provider trust to past 30-day adherence via medication beliefs (β = .194; SE = .148;
95% CI: .012 to .604). The necessity beliefs path was significant (β = -.226; SE = .163; 95% CI:
-.012 to .604) but the concern beliefs path was not. Additional models were not significant.
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These results confirm that the necessity-concerns difference score provided a more sensitive test
of the hypotheses in this study.
Discussion
The present study is the first to examine the indirect effect of the patient-provider
relationship on both HIV medication adherence and intentional nonadherence through
medication beliefs. Findings from this sample of 116 HIV-infected adults provide support for the
importance of patients’ beliefs about medications in the patient-provider to adherence
relationship. In keeping with the first major hypothesis, provider trust and satisfaction showed
positive associations with both adherence outcomes. Contrary to predictions, the hypothesized
association of patient-provider relationship to intentional nonadherence was largely not
supported. Only provider trust was negatively associated with past month intentional adherence,
and not lifetime intentional nonadherence. Provider satisfaction was unrelated to both intentional
nonadherence outcomes.
The primary aim of this study was to examine the role of patient’s medication beliefs in
the patient-provider to adherence relationship. The second major hypothesis, that there would be
a significant positive indirect effect of the patient-provider relationship to adherence through
medication beliefs received strong support, particularly in the context of provider satisfaction.
Study findings confirmed an indirect effect of provider satisfaction and both general adherence
outcomes via medication beliefs. Thus, findings provide preliminary evidence that a patient’s
level of satisfaction with and trust in their providers influences whether they internalize the
information provided by the providers, and that information may in turn influence decisions
about adherence.
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With regard to provider trust, there was a significant indirect effect for past month, but
not past week adherence through medication beliefs. An alternative model with provider trust as
the mediator found an indirect effect of medication beliefs to past month and past week
adherence via provider trust. This finding raises the possibility that patient’s medication beliefs
also influence a patient’s perception of their providers. One possibility is that if a patient’s
preconceived medication beliefs are congruent with the message from their providers, the patient
is more likely to adhere to their medications. When the message received by patients is at odds
with their beliefs, the patient may feel dissatisfied with their care or distrustful of their providers
leading to poorer adherence. Negative medication beliefs may also reflect a more general
skepticism or distrust of healthcare. Longitudinal data are needed to confirm the directionality of
these effects.
An important and understudied area of HIV behavioral research concerns the role of
intentional nonadherence, where volitional decisions by patients are made to alter their
medication regimen. These deliberate decisions are a related yet separate phenomena from
adherence which has led some to hypothesize they may be a product of a poor patient-provider
relationship (Norton et al., 2010). In this study, it was hypothesized that a better patient-provider
relationship would lead to more positive medication beliefs, and in turn less engagement in
intentional nonadherence. In this sample, only provider satisfaction to lifetime intentional
nonadherence through medication beliefs was significant. Provider trust was largely unrelated to
intentional nonadherence. Of note, lifetime intentional nonadherence may reflect experiences
with previous providers or older classes of HIV medication which have poorer adherence rates
(e.g., Heath et al., 2002). Given the relative lack of association between study variables with
intentional nonadherence, a spurious finding cannot be ruled out.
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For PLWHA, a variety of patient-specific factors influence medication adherence,
including adherence self-efficacy, substance use, depressive symptoms, social support, and
demographic factors (Langebeek et al., 2014). The present research expands beyond a focus on
individual level factors to consider the influence of patient perceptions of their provider in
relation to medication adherence. Future research can extend the present findings by considering
the role of patient-provider influences within a broader framework of both individual, contextual,
and dyadic factors related to adherence. Self-regulation models provide a unifying framework
that allows for a better understanding of how multiple factors interact to influence an individual’s
understanding of their illness and subsequent health behaviors related to treatment (Levanthal et
al., 1997). According to self-regulation theory, patient’s construct schemas about their illness
based on factors such as culture, previous experience, and interactions with others, including
their healthcare providers. A better understanding of the interplay among these variables can aid
in our understanding of how patient-provider relationships influence adherence within the
broader context of the multitude of factors that have been linked with adherence and related
outcomes.
Overall, while additional work is needed, this study points to the potential importance of
dialogue between patients and providers. The quality of the patient-provider relationship sets the
stage for patient education by building trust and shared satisfaction. With an increasingly costdriven environment where providers face-to-face time with patients is often limited, providers
are challenged to build rapport and efficiently communicate with their patients. Although more
research is needed, these initial findings point to the possibility that medical training should
emphasize the development of communication skills in addition to medical expertise. It may also
be beneficial for healthcare organizations to assess patient’s perceptions of their providers,
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particularly in the context of chronic illness which require high levels of medication adherence.
Such feedback, where low trust or satisfaction is evident, can help organizations and providers
improve patient outcomes through interventions aimed at improving doctor-patient relationships.
This study has several limitations, the first being the modest sample size and crosssectional nature of these data which precludes causal inference. Although these findings point to
the possibility that patient-provider relations influence beliefs rather than vice-versa, longitudinal
data would help provide clearer evidence of the temporal sequencing of these effects. Our
sample was recruited from an outpatient IV clinic; researchers are encouraged to examine these
findings in underserved communities such as rural areas or individuals without consistent care
(e.g., Stepleman, et al., 2006). Additionally, this project framed provider trust and satisfaction as
separate variables. It may be that a model that includes both variables simultaneously or controls
for one another is a better fit for these data. It is possible that provider trust and satisfaction
reflect a more general attitude toward their providers rather than separate but related constructs.
Future research should test such models to determine if they better explain the relationship
between these variables.
Strengths of this study include a demographic makeup that is representative of PLWHA
at large and is consistent with other samples of outpatient HIV patients (e.g., Beach et al., 2013;
Cambiano et al., 2010). Methodologically, this study used a well-established measure of
medication beliefs (Horne et al., 2013) and two previously developed measures of adherence and
intentional nonadherence. This study’s inclusion of intentional nonadherence is novel and adds
to the paucity of literature on this variable.
In conclusion, the results of the present study suggest that one mechanism through which
the patient-provider relationship influences medication adherence may be patients’ beliefs about
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their medications. These data provide preliminary evidence that the quality of a patient’s
perceived relationship with their providers and their beliefs about medications are relevant
factors that exert an influence on HIV medication adherence and may be useful predictors of
adherence. Providers are encouraged to focus attention on building strong rapport, trusting
relationships and overall satisfaction to set the stage for effective patient education. Ensuring
they educate patients about the necessity of taking medication and alleviating any concerns may
improve patient outcomes and health.
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Provider Trust

Adherence (Y1)

Provider
Satisfaction

Intentional nonadherence (Y2)

Necessity - Concerns

Figure 1. Conceptual model. The effect of provider trust and provider satisfaction on Adherence
(Y1) and Intentional nonadherence (Y2) with beliefs about medications (Necessity/Concerns
differential) as a mediator.
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Table 1. Demographic and Summary Statistics
Variable

M
45.35

SD
8.60

Provider Trust

4.59

.86

Provider Satisfaction

4.38

1.01

Necessity/Concerns

2.24

1.13

Necessity

4.33

.57

Concerns

2.46

.64

2.04

1.16

Age (years)
Less than High School
High School diploma
Some College or Degree
Gender
Male
Female
Transgender
Race
African American
White
Multiracial or Other
Currently Employed

(n)

(%)

22
41
53

19
35.3
20.5

67
47
2

57.8
40.5
1.7

50
54
12
44

43.1
46.6
10.3
37.9

Past Week Adherence

92.48

Past Month Adherence

89.70

Lifetime Intentional
Nonadherence*
Past Month Intentional
Nonadherence
Note: n = 116.

17.69
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Table 2. Bivariate Correlations Between Primary Variables
Variable

1.

2.

3.

4.

5.

6.

7.

8.

1.Trust

-

2.Satisfaction

.65*

-

3.Necessity/Concerns

.39*

.26*

-

4.Necessity

.35*

.04

.74*

5.Concerns

-.26* -.34* -.80* -.19* -

6.Past week adherence

.34*

.21*

.26*

.18

-.22* -

7.Past month adherence

.18*

.23*

.23*

.25*

-.12

.36*

-

8.Intentional – Lifetime

-.08

-.05

-.19* -.13

.16

-.14

-.41* -

9. 10.

-

9.Intentional – past 30-day -.24* -.13 -.17 -.20* .08
-.53* -.46* .25* Note: Correlations represent Pearson’s r, * p < .05, Past month adherence: 0 = ≤ 95%, 1 = ≥
95%.
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Table 3. Path Results for Simple Mediation Models.
Model 1. Trust → BMQ → Adherence
B
SE
(a) Trust → BMQ
0.610
0.108
(b) BMQ → Adherence past week
1.690
1.528
(c’) Trust → Adherence past week
6.309
1.991
(b) BMQ → Adherence past month
.372
.195
(c’) Trust → Adherence past month
.266
.253
Model 2. Satisfaction → BMQ → Adherence
B
SE
(a) Satisfaction → BMQ
0.289
0.101
(b) BMQ → Past week
3.331
1.441
(c’) Satisfaction → Past week
2.707
1.610
(b) BMQ → Past month
.442
.188
(c’) Satisfaction → Past month
.014
.198
Model 3. Trust → BMQ → Intentional
B
SE
Nonadherence
(b) BMQ → Past month
-1.855
2.067
(c’) Trust → Past month
-4.534
2.691
(b) BMQ → Lifetime
-.183
.108
(c’) Trust → Lifetime
-.030
.140
Model 4. Satisfaction → BMQ → Intentional
B
SE
Nonadherence
(b) BMQ → Past month
-3.023
1.912
(c’) Satisfaction → Past month
-1.936
2.128
(b) BMQ → Lifetime
-.195
.099
(c’) Satisfaction → Lifetime
.003
.110
Note: * p < .05, ** p < .01. BMQ = Beliefs about Medicines questionnaire.

T
5.655
1.106
3.168
Z: 1.905
Z: 1.052
T
2.854
2.312
1.681
Z: 2.351
Z: .069
T

P value
<.001**
0.271
.002**
.057
.293
P value
0.005**
0.023*
0.095
.019*
.945
P value

-.897
-1.685
-.1701
-.217
T

.372
.095
.092
.829
P value

-1.581
-.910
-1.977
.026

.117
.365
.05*
.979
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Table 4. Bootstrap Estimates of the 95% CIs for the Indirect Effects.
Indirect effects
Adherence
1a Trust → BMQ → 7-day Adhere
1b Trust → BMQ → 30-day Adhere
2a Satisfaction → BMQ → 7-day Adhere
2b Satisfaction → BMQ → 30-day Adhere
Intentional Nonadherence
3a Trust → BMQ → Past month
3b Trust → BMQ → Lifetime
4a Satisfaction → BMQ → Past month
4b Satisfaction → BMQ → Lifetime
Alternative Models
BMQ → Trust → Past Month
Trust → Necessity & Concerns → Past Month

OR

B

SE

CI (LB) CI (UB)

.184
.127

1.169
.961
-

.872
.990
.634
.084

-.197
.251
.126
.021

3.429
4.140
2.710
.344

-

-.989
-.099
-.854
-.056

1.073
.064
.667
.036

-3.155
-.262
-2.630
-.153

.966
.004
.104
-.004

1.731 1.101 .232
.194 .148 .012

4.860
.604

Note: CI (LB) and CI (UB) represent the lower and upper bound of a 95% bootstrapped
confidence interval with 10,000 resamples. BMQ = Beliefs about Medicines questionnaire.
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Appendix A.
Patient-Provider Relationship Scale
Tinst1. We are interested in your relationship with your HIV care providers. The following
questions ask about your relationship with the providers who are most involved in your HIV
care. For example, the people who talk to you about how to take meds or get you started on
meds; or the people who see you when you have an emergency. Remember, your responses will
not be shared with any of your providers. We want to know how you truly feel about your HIV
care providers.
1  Poor
2  Fair
3  Good
4  Very Good
5  Excellent
How are your HIV care providers at…
Overall Communication
T1. …explaining the results of tests in a way that you understand?
T2. …giving you facts about the benefits and risks of treatment?
T3. …telling you what to do if certain problems or symptoms occur?
T4. …demonstrating caring, compassion, and understanding?
T5. …understanding your health worries and concerns?
HIV-specific Information
T6. …talking with you about your sex life?
T7. …asking about stresses in your life that may affect your health?
T8. …at asking about problems with alcohol?
T9. …at asking about problems with street drugs like heroin and cocaine?
Adherence
T10. …giving you information about the right way to take your HIV medicines?
T11. …understanding the problems you have in taking your HIV medicines?
T12. …helping you solve problems you have taking your HIV medicines the right way?
Participatory Decision-making
T13. How often do your HIV care providers ask you to take some of the responsibility for your
treatment?
1  Never
2  Rarely
3  Sometimes
4  Often
5  Very often
T14. If there was a choice between treatments, would your provider ask you to help make the
decision?
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1  Definitely Not
2  Probably Not
3  Uncertain
4  Probably Yes
5  Definitely Yes
T15. How often do your HIV care providers make an effort to give you some control over
treatment decisions?
1  Never
2  Rarely
3  Sometimes
4  Often
5  Very often
T16. How often do your HIV care providers offer choices in your medical care?
T17. How often do your HIV care providers discuss the pros and cons of each treatment option
with you?
T18. How often do your HIV care providers get you to state which treatment option you would
prefer?
T19. How often do your HIV care providers take your preferences into account when making
treatment decisions?
1  None of the time
2  A little of the time
3  Some of the time
4  Most of the time
5  All of the time
Overall Satisfaction with Provider
1  Poor
2  Fair
3  Good
4  Very Good
5  Excellent
T20. Overall, how would you rate your provider’s personal manner (e.g., courtesy, respect,
sensitivity, friendliness)?
T21. How would you rate your provider’s communication skills (e.g., listening carefully,
answering questions, giving clear explanations)?
T22. How would you rate your provider’s technical skills (e.g., thoroughness, carefulness,
competence)?
Trust in Provider
Tinst2. Thinking about how much you trust your HIV care provider, how strongly do you agree
or disagree with the following statements?
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1  Strongly Disagree
2  Disagree
3  Somewhat disagree
4  Somewhat agree
5  Agree
6  Strongly Agree
T23. I can tell my HIV care provider anything, even things that I might not tell anyone else.
T24. My HIV care provider cares more about holding down costs than about doing what is
needed for my health.
T25. My HIV care provider cares as much as I do about my health.
T26. All things considered, how much do you trust your HIV care provider?
1  Not at all
2  Only a little
3  Somewhat
4  Quite a bit
5  Completely
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Appendix B.
Beliefs about Medications Questionnaire
Rinst1. Next, you will hear statements that other people living with HIV have made about HIV
meds. Please tell us how much you AGREE or DISAGREE with each statement be checking the
response that best fits for you. There are no right or wrong answers. Please tell us how you really
feel about medications for HIV.
1  Strongly Disagree
2  Disagree
3  Somewhat disagree
4  Somewhat agree
5  Agree
6  Strongly Agree
C
R1. My HIV meds give me unpleasant side-effects.
N
R2. My health depends on HIV medications.
C
R3. Taking HIV meds is embarrassing.
N
R4. Without HIV meds, I would become very ill.
N
R5. My health in the future will depend on HIV medications.
C
R6. HIV medications are a mystery to me.
N
R7. HIV medications keep HIV under control.
N
R8. HIV meds can keep me alive.
C
R9. Having to take HIV meds worries me.
C
R10. I sometimes worry about the long-term effects of HIV medications.
C
R11. HIV medications disrupt my life.
N
R12. Missing HIV medications for a day won’t matter in the long run. (R)
C
R13. I sometimes worry about becoming too dependent on HIV medications.
C
R14. I am unlikely to get a bad side-effect from my meds in the next month. (R)
N
R15. HIV meds are my best hope for the future.
C
R16. Taking HIV meds has been much worse than I expected.
C
R17. I have received enough information about HIV medications. (R)
N
R18. My life would be impossible without HIV meds.
C
R19. The taste of my meds makes me feel unwell.
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Appendix C.
Intentional Nonadherence

Instructions
The next questions will ask about your HIV meds. We understand that there are many challenges
to taking HIV medications and many people struggle to take their pills as prescribed. Some
people find it hard to take their pills according to all the special instructions. Some people get
busy and forget to carry their pills with them and others decide to skip doses to avoid side effects
or to just not be taking pills that day. Telling us about your actual experiences with HIV meds
will help us to get a better understanding of what is needed to improve HIV care. So please
answer honestly and do not worry about telling us that you don't take your pills perfectly, your
answers are completely confidential.
People have different experiences regarding the decision to start taking HIV medications. Please
take a moment to think about your own experience deciding to start taking HIV medications.
Think about all the times that you and your doctor or nurse practitioner talked about HIV
medications since you were diagnosed.
O1. Has your doctor or nurse practitioner ever recommend that you start taking HIV medications
and you decided that it was not the right time for you?
 No (skip to O2)
Yes
O1a. On how many separate occasions has your doctor or nurse practitioner discussed the need
for you to begin HIV medications and you decided not to?
#_
O2. Thinking again about the time since you very first started taking HIV meds, have you ever
stopped taking one or more of your meds for any reason?
 No (skip to O3)
Yes
O2a. On how many separate occasions have you stopped taking one or more of your HIV meds
for more than a day?
#_
O2b. On how many of these occasions was your decision to stop based on a recommendation
from your HIV doctor?
#_
O2c. On how many of these occasions did you decide not to tell your doctor or nurse practitioner
that you had stopped taking one or more of your HIV meds?
#_
O3. Some people we have talked to say that they sometimes take “medication vacations”
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– meaning that they decide to take a break from taking some or all of their medication for a
period of time.
Since you started HIV meds, have you ever taken a break from your meds, even for just one day?
1 No (Skip to O3b)
2 Yes
O3a. How many separate times have you taken a break from your HIV meds for one or more
days
(Go to O3c) O3b. Even if you haven’t actually taken a break from your HIV meds, how often do
you think of taking a break?
1 Almost everyday
2 At few times a month
3 A few times a year
4 A few times ever
5 Never
O3c. Have you ever discussed taking a break from your meds with your doctor or nurse?
1 No
2 Yes
Instructions
Some people we have talked to say that sometimes they make small adjustments to how they take
their HIV medications because they are having side effects, because they had a change in their
plans for the day, they were feeling depressed, or for other reasons.
O4a. Since you started taking HIV medications, have you ever…
…taken less of a medication than was prescribed? Yes No
O4b. Since you started taking HIV medications, have you ever…
…taken a medication dose significantly later than you had scheduled?

Yes

O4c. Since you started taking HIV medications, have you ever…
…taken two doses at the same time to make up for a previous missed dose?

No

Yes No

O4d. Since you started taking HIV medications, have you ever…
…skipped the special instructions for your medication, like “with meals”, “on an empty
stomach”, “every 8 hours”, or “with plenty of fluids” Yes No
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Appendix D.
Last Month Adherence
Instructions. For the next question, please look at HANDOUT A.
Put a mark on the line below at the point that shows your best guess about how much of your
prescribed HIV medication you have taken in the last month. We would be surprised if this were
100% for most people.
For example:
0% means you have taken no medication
50% means you have taken half your medication
100% means you have taken every single dose of your medication Click ‘Continue’ once
Instructions. For this question, please look at HANDOUT B. Again, there is a scale marked 0
to 100.
Put a mark on the line below at the point that shows your best guess about how often you made
small adjustments in how you take your HIV meds over the past month. We would be surprised
if this were 0% for most people.
For example: 0% means you never make small adjustments to your regimen 50% means you
make small adjustments about half the time 100% means that you always make small adjustments
to your regimen
Click 'Continue' once you have completed HANDOUT B.
Instructions. For this question, please look at the scale on HANDOUT C.
Some people we have talked to say that they sometimes skip a dose of their HIV medication for
personal reasons.
In the past month, HOW OFTEN have you skipped a dose of your HIV meds because you were
having side effects, had a change in your plans, felt depressed, or for some other reason?
For example:
100% means you skipped every dose of your meds.
50% means that you skipped about half of your doses
0% means that you never skipped a dose in the past month Click 'Continue' once you have
completed
OK, you’ve made it to the last questions about your meds! Great work!
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Appendix E.
Past week Adherence
For this last section, please look at the calendar that you filled out with the research assistant just
a few minutes ago. Remember that you filled in the number of pills that you are supposed to take
for your HIV for each day in the past week.
O5a. How many of your pills did you forget to take OR decide to skip on DAY 1?
O5b. Day 2
O5c. Day 3
O5d. Day 4
O5e. Day 5
O5f. Day 6
O5g. Day 7
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HANDOUT A
Put a mark on the line below at the point that shows your best guess about how much of your prescribed HIV medication you have
taken in the last month. We would be surprised if this were 100% for most people.
Examples:

0% means you have taken no medication
50% means you have taken half your medication
100% means you have taken every single dose of your medication
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HANDOUT B
Put a mark on the line below at the point that shows your best guess about how often you made small adjustments in how you
take your HIV meds over the past month. We would be surprised if this were 0% for most people.
Examples:

0% means you never make small adjustments to your
regimen 50% means you make small adjustments about
half the time
100% means that you always make small adjustments to your regimen
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HANDOUT C
Put a mark on the line below at the point that shows your BEST GUESS about how often in the past month you skipped a dose of
your HIV meds because you were having side effects, had a change in your plans, felt depressed, or for some other reason. We would
be surprised if this were 0% for most people.
Examples:
100% means you skipped every dose of your meds.
50% means that you skipped about half of your doses
0% means that you never skipped a dose in the past month
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Appendix F.
Demographic & Health History Questions
A1. What is your gender?

1  Female

A2. How old are you?

_____ years old

A3a. In what year were you born?

2  Male

3  Transgender

______

A3b. In what month were you born? ______
A3c. On what day of the month were you born?

_____

A4. What is the highest level of education that you have completed?
1  Less than high-school
2  High-school diploma or GED
3  Some college
4  Associates degree or Technical Certification
5  Bachelors degree
6  Masters degree
7  Doctoral degree
A5. Which of the following BEST describes your racial/ethnic background? Is it…
1  Native Hawaiian or Other Pacific Islander
2  Black or African-American
3  White/Caucasian
4  Asian
5  American Indian or Alaska Native
6  Mixed or Multi-racial
A6. Do you consider yourself to be Hispanic/Latina/Latino?
1  No

2  Yes

A7. Which of the following statements applies best to you?
1  I am sexually attracted to men.
2  I am sexually attracted to men and women.
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3  I am sexually attracted to women.
A8. Which best describes your current relationship status?
1  In a committed relationship
2  Single and dating one or more people
3  Single and interested in dating but not currently dating
4  Single and not interested in a relationship at all
A9. Are you married?
1  No

2  Yes

A10. Is English your first language?
1  No

2  Yes

A11. Are you currently employed?
1  No (skip to A12)

2  Yes (go to A11a)

A11a. On average, how many hours per week do you work?
1  Less than 10 hours
2  10 – 20 hours
3  21 – 39 hours
4  40+ hours
A12. Approximately how much money do you have to live off of in an average MONTH?
This includes money that goes toward paying your rent, utilities, and other monthly bills.
Monthly income: $ ________
A13. From which of the following sources do you regularly receive income? (check all that
apply)
1  Wages or salary from job
2  Unemployment
3  Welfare
4  Disability
5  Spouse/Partner
6  Family
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7  Friends
A14. In what year were you diagnosed with HIV? _______
A15. What was your most recent viral load result?
1  Undetectable
2  Detectable
3  Don’t know
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